Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial

ग्रंथसूची विवरण
मुख्य लेखकों: De Botton, S, Risueño, A, Schuh, AC, Lowenberg, B, Kim, H-J, Vyas, P, Wei, AH, Stein, EM, Dohner, H, Fathi, AT, Dinardo, CD, Martin Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M
स्वरूप: Conference item
भाषा:English
प्रकाशित: American Society of Clinical Oncology 2022
विवरण
सारांश:

समान संसाधन